Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, shows significant weight loss in obese patients in Phase 2 VENTURE trial, with up to 14.7% reduction from baseline.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.